A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies

Trial Profile

A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs PIM 447 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 19 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 04 Nov 2015 Planned End Date changed from 1 Feb 2018 to 1 Jan 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top